Back To: Home

January 19-23, 2015
PepTalk - San Diego, CA

February 7-11, 2015
SLAS2015 - Washington, DC

More Events

Islet Sciences acquires DiaKine, gains diabetes therapeutic
April 2012

NEW YORK—Islet Sciences Inc. recently announced the establishment of a Share Exchange Agreement to acquire DiaKine Therapeutics Inc. (DTI), a biopharmaceutical company focusing on developing therapeutics for diabetes sufferers. Islet Sciences agreed to issue an aggregate of 200,000 shares of its Series C preferred stock in exchange for all issued and outstanding shares of DTI, in addition to issuing 100,000 shares of common stock to certain of DTI's creditors in satisfaction of DTI's liabilities outstanding as of the agreement's closing. Each share of Series C preferred stock is convertible into 10 shares of common stock.  
"DiaKine's drugs have the potential to reshape the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease … We believe this acquisition will position us to capitalize on the exciting opportunities emerging in our industry," said John Steel, chairman and CEO of Islet Sciences.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.